2
Record financing rounds at the Munich biotech hub
One document
more
Stories about Pharmaindustrie
- Language:
- Media:
- Period:
- Period:Total
Press release: STADA continues strong growth journey in the first half of 2024
One documentmorePress release: Alvotech and STADA add to strategic alliance through denosumab partnership
Alvotech and STADA add to strategic alliance through denosumab partnership - STADA assumes marketing license for Alvotech’s proposed biosimilar referencing Prolia®/Xgeva® (denosumab) in Europe, including Switzerland and the UK, as well as rights in selected markets in Central Asia and the Middle ...
One documentmorePress release: STADA welcomes CHMP positive opinion on extending indication for Kinpeygo
STADA welcomes CHMP positive opinion on extending indication for Kinpeygo - The CHMP adopted a positive opinion recommending a change to the terms of the marketing authorization of Kinpeygo for the treatment of adults with primary immunoglobulin A, now covering patients with a UPCR of ≥0.8 g/g - ...
One documentmorePress release: Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK
Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK - Bio-Thera and STADA have reached an exclusive commercialization and license agreement for BAT2506, a biosimilar candidate to Simponi® ...
One documentmorePress release: STADA reduces carbon emissions and increases its renewable energy supply on sustainability journey
STADA reduces carbon emissions and increases its renewable energy supply on sustainability journey - Total carbon emissions by STADA reduced by 25% between 2020 and 2023 - Around 45% of STADA’s electricity consumption now comes from renewable ...
One documentmorePress release: STADA continues with double-digit sales and profit growth in 2023
One documentmorePress release: STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara - Marketing authorization issued in European Economic Area for Uzpruvo®, the first biosimilar to Stelara®, a biologic therapy within ...
One documentmorePress release: Zuellig Pharma becomes STADA Philippines’ exclusive distribution partner
One documentmore- 2
Press release: STADA's excellent results in H1 2023 indicate a record annual profit of €1 bn, driven by Consumer Healthcare and Specialty
One documentmore - 2
Press Release: Aurubis subsidiary RETORTE expanding selenium production for profitable growth markets
One documentmore Gerresheimer with a good start to 2023 financial year: Again double-digit growth in revenues and Adjusted EBITDA
Düsseldorf (ots) - - First-quarter revenues grew organically by 21.0% - Adjusted EBITDA up organically by 24.8% - Gerresheimer confirms guidance for financial year 2023 Gerresheimer AG, a leading provider of healthcare & beauty solutions and drug ...
One documentmorePress release: STADA and Xbrane launch ranibizumab to support patient access in Europe
STADA and Xbrane launch ranibizumab to support patient access in Europe - Ranibizumab biosimilar is being launched in major European markets - Ranibizumab is the first product brought to market through a strategic collaboration between STADA and Xbrane, marking Xbrane’s first commercial launch and ...
One documentmorePress release: STADA sustains strong momentum with double-digit sales and profit growth in 2022
One documentmoreInnovation and Start-up Center Biotechnology (IZB) welcomes Invitris
One documentmorePress release: EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab) - Partners Alvotech and STADA have marketing authorization application (MAA) for ustekinumab accepted for filing by the European Medicines Agency (EMA) ...
One documentmorePress release: STADA appoints Boris Döbler as Chief Financial Officer
One documentmorePress release: Alvotech and STADA Broaden Access to Adalimumab Biosimilar in Europe
Alvotech and STADA Broaden Access to Adalimumab Biosimilar in Europe - Launches in Belgium, Bulgaria, Croatia, Czech Republic, Latvia, Romania, and Slovenia, increasing availability of high-concentration, citrate-free adalimumab in Europe - Follows initial introduction of adalimumab in ninecountries: ...
One documentmoreGerresheimer to expand significantly in High Value Solutions and further accelerates its sustainable profitable growth
Düsseldorf (ots) - At today’s Capital Markets Day, Gerresheimer AG, a leading provider of healthcare & beauty solutions and drug delivery systems for pharma, biotech and cosmetics, reaffirmed its growth agenda and increased its revenue and adjusted ...
One documentmorePress release: Stéphane Jacqmin joins STADA from Sanofi and becomes Head of Emerging Markets
One documentmorePress release: STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®
STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis® - European Commission grants pan-EU marketing authorization for Ximluci® biosimilar referencing Lucentis® (ranibizumab) - Paves way for European ...
One documentmoreBrenntag’s Pharma section signs exclusive agreement for health-promoting product line Akovita ELIP in EMEA
One documentmore- 2
The start-up Eisbach Bio in the IZB near Munich receives 6.7 million euros from the Bavarian state government for the development of a COVID-19 therapeutics
One documentmore - 2
COVID-19: Start-up Eisbach Bio at the IZB receives EUR 8 million government grant
One documentmore - 7
Biotech start-ups at the IZB close deals worth more than 140 million EUR in the first half of 2021
One documentmore Origenis founds biotech company Neuron23 in Silicon Valley together with star investor Kleiner Perkins
One documentmore- 3
World Cancer Day: Start-ups at the IZB develop innovative cancer drugs and diagnostic tools
One documentmore - 5
Commemorative publication for the 25th anniversary of the IZB presents 70 profiles and visions of successful biotech start-ups
One documentmore Fresenius achieves record Q3 earnings - improves 2011 earnings outlook
Bad Homburg (ots) - Q1-3 2011: - Sales EUR 12.1 billion, +2% at actual rates, +5% in constant currency - EBIT EUR 1,862 million, +5% at actual rates, +9% in constant currency - Net income EUR 565 million, +14% at actual rates, +17% in constant currency - Fresenius improves 2011 earnings1 outlook of 15% ...
One documentmore
1